Alembic Pharmaceuticals announces executive resignation and USFDA approval

Alembic Pharmaceuticals [BSE: 533573] announced the resignation of Mr. Viraj Save, Executive Vice President, Sales and Marketing, effective May 31, 2025. The company notified the exchange of this change under Regulation 30 of SEBI guidelines. Separately, Alembic announced it had received USFDA final approval for its Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. This approval covers a drug therapeutically equivalent to Doxil Liposome Injection by Baxter Healthcare Corporation, used to treat Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma. The estimated market size for Doxorubicin Hydrochloride Liposome Injection is USD 29 million for the twelve months ending March 2025 according to IQVIA. Alembic now holds a cumulative total of 224 ANDA approvals from the USFDA.